NV-AQARA
8.1.2024 18:01:32 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its participation in CES 2024. At the event, Aqara will showcase its latest innovations, including the new Border Router Plug and Smart Lock U300, as well as other advanced smart home solutions and prototypes at its booth in the Venetian Expo (#53513).
Aqara is an early advocate of the industry-unifying Matter standard and is committed to delivering seamless smart home experiences for users. The Border Router Plug and Smart Lock U300 will be Thread-capable, which will add to Aqara's growing number of native Matter products, making Aqara devices more interoperable. These two new products previewed at CES are expected to become available for order in the coming months.
Border Router Plug
The Aqara Border Router Plug represents an innovative advancement in smart plug and is among the first smart plugs announced to incorporate Thread Border Router capabilities. Equipped with Thread and dual-band Wi-Fi, this plug enables Matter controllers without Thread capability to manage Thread devices, allowing seamless integration of Thread devices into smart home systems without needing a new Matter controller.
This plug is energy-efficient, particularly in Thread-only mode, which reduces idle consumption while extending the mesh Thread network by routing the data packets. It is also energy-conscious, providing real-time and historical data on home energy consumption, enabling users to automate their electrical devices to reduce energy waste. Additionally, the Border Router Plug can sense the on/off status of the connected appliance and trigger Aqara Home automations accordingly. For example, users can have the curtains close automatically when the TV is on to eliminate potential sun glare.
The Aqara Border Router Plug utilizes an NXP® Semiconductors' secure wireless MCU. As part of the ongoing collaboration between Aqara and NXP Semiconductors, the Border Router Plug will also be featured in NXP's Smart Home Experience showcase during CES 2024, along with the NXP-powered Aqara Door and Window Sensor P2.
Smart Lock U300
The Aqara Smart Lock U300 is one of the first smart lever locks announced to feature Matter and Thread compatibility, and offers unprecedented interoperability with various smart home platforms. This versatility is coupled with an extended battery life of up to 8 months and enhanced local control, which improves responsiveness, privacy and security.
Designed for both indoor and outdoor use, the U300 replaces the traditional US lever or knob on single-bore doors and is ideal for including side entries, garage entries, home offices, basements and storage rooms. It enables a key-free lifestyle with multiple access options, including fingerprints, PIN codes, NFC, or voice assistants. Homeowners can control the lock remotely, grant temporary access to guests, and receive real-time notifications of who comes and goes - all from a smartphone.
Aqara Home App Update
At CES 2024, Aqara will also showcase Home Copilot, the new chatbot interface for the Aqara Home app, which is powered by Gen-AI. Home Copilot is designed to enhance user experiences by utilizing ambient intelligence, which helps convert real-time data and insights into actions. Ultimately, Home Copilot will be able to analyze the usage patterns in an Aqara home and proactively suggest customized automations. It will also understand natural language and configure automations per user requests. Users can automate their homes via simple voice and text instructions, which makes smart home even more intuitive and easy to use.
Initially, Home Copilot will enable Aqara Insights, a daily, weekly and monthly smart home reports for users, and provide tailored plans for energy-saving automation. It will support natural language queries for Aqara devices and automations and offer proactive assistance with device setup and troubleshooting. Home Copilot will also spearhead the AI-powered customer support interface for Aqara users in over 10 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108777203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom